Cyprotex has had a very strong first nine months in its 2015 financial year with the group flagging that performance has exceeded expectations. As a result, the group anticipates that its full year revenues and EBITDA will exceed market expectations. We upgrade our 2015 forecasts for the second time since the trading update in June. We believe Cyprotex has the ability to continue to expand its service offering, attract new customers and expand into new end markets.


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Trading ahead of expectations
Cyprotex has had a very strong first nine months in its 2015 financial year with the group flagging that performance has exceeded expectations. As a result, the group anticipates that its full year revenues and EBITDA will exceed market expectations. We upgrade our 2015 forecasts for the second time since the trading update in June. We believe Cyprotex has the ability to continue to expand its service offering, attract new customers and expand into new end markets.